Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies

1 Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973?1999, featuring implications of age and aging on the U.S. cancer burden. Cancer. 2002; 94:2766?92.
2 Adams VR, Sheehan JB, Holdsworth MT. Guide to cancer chemotherapy regimens. Pharm Pract News. 2001; Nov(suppl):33?45.
3 Abel EA. Immunosuppressant and cytotoxic drugs: unapproved uses or indications. Clin Dermatol. 2000; 18:95?101.
4 Naumann BD, Sargent EV, Starkman BS et al. Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J. 1996; 57:33?42.
5 White SK, Stephens AD, Dowjat B et al. Safety considerations in the use of intraoperative intraperitoneal chemotherapy. Cancer Treat Res. 1996; 82:311?6.
6 Takada S. Principles of chemotherapy safety procedures. Clin Tech Small Anim Pract. 2003; 18:73?4.
7 Sessink PJ, Anzion RB, van der Broeck PH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16?22.
8 Sessink PJ, Boer KA, Scheefhals AP et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105?12.
9 McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57?60.
10 Sessink PJ, Cerna M, Rossner P et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994; 309:193?9.
11 Sessink PJ, van de Kerkhof MC, Anzion RB et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994; 49:165?9.
12 Mader RM, Rizovski B, Steger GG et al. Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health. 1996; 51:310?4.
13 Sessink PJ, Wittenhorst BC, Anzion RB et al. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997; 52:240?4.
14 Connor TH, Anderson RW, Sessink PJ et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J HealthSyst Pharm. 1999; 56:1427?32.
15 Minoia C, Turci R, Sottani C et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom. 1998; 12:1485?93.
16 Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health-Syst Pharm. 2002; 59:956?61.[Free Full Text]
17 Pethran A, Schierl R, Hauff K. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003; 76:5?10.
18 Turci R, Sottani C, Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Tox Lett. 2002; 134:57?64.
19 Wick C, Slawson MH, Jorgenson JA et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314?20.
20 Peters BG, Bing MR, Harrison BR. Surface contamination with fluorouracil and cyclophosphamide in three pharmacies and clinics using standard techniques versus the PhaSeal containment system. Paper presented at ASHP Midyear Clinical Meeting. New Orleans, LA; 2003 Dec 9.
21 National Institute for Occupational Safety and Health. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. www.cdc.gov/niosh/docs/2004?165/(accessed 2004 Dec 1).
22 Sessink PJ, Rolf MA, Ryd?n NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34:1311?7.
23 Connor TH, Anderson RW, Sessink PJ et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an admixture area. Am J Health-Syst Pharm. 2002; 59:68?72.
24 Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health. 1997; 70:209?14.
25 Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001; 6:146?52.
26 Spivey S, Connor TH. Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm. 2003; 38:135?9.
27 Ros JJ, Simons KA, Verzul JM et al. [Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center.] Ziekenhuisfarmacie. 1997; 13:168?71. In Dutch.
28 Hepp R, Gentschew G. [External contamination of commercially available cytotoxic drugs.] Krankenhauspharmazie. 1998; 19:22?7. In German.
29 Paul H, Baumann L, Artelt S et al. Umgebungskontrolle auf contamination mit zytostatika: nachweis von platin auf oberfl?chen in r?umlicheiten mit zentraler zytostatikaherstelling. Krankenhauspharmazie. 1998; 4:181?6.
30 Delporte JP, Chenoix P, Hubert PH. Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur Hosp Pharm. 1999; 5:119?21.
31 Nygren O, Gustavsson B, Str?m L et al. Cisplatin contamination observed on the outside of drug vials. Ann Occup Hyg. 2002; 46:555?7.
32 Favier B, Gilles L, Ardiet C et al. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Pract. 2003; 9:15?20.[CrossRef]
33 Mason HJ, Morton J, Garfitt SJ et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg. 2003; 47:681?5.
34 Funck von S, Schierl R. Sicherheit bei der zytostatikahersatellung. Dtsch Apoth Ztg. 2004; 10:1089?94.
35 Wilken A. Boebachtungen zur au?enkontamination der prim?rvpackungen von zytostatika. Krankenhauspharmazie. 1997; 1:37?9.
36 Larson RR, Khazaeli MB, Dillon HK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health-Syst Pharm. 2002; 59:270?7.
37 Sottani C, Turci R, Perbellini L et al. Liquid?liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Comm Mass Spectrom. 1998; 12:1063?8.
38 Sessink PJ, Scholtes MM, Anzion RB et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993; 616:333?7.
39 Metrohm Application Bulletin No. 220/1. Voltammetric determination of platinum and rhodium in the ultratrace range. www.metrohm.com (accessed 2005 Jan 6).
40 Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993; 15:191?219.
41 Wachsmuth J, Kittlaus W. Cytotoxics: reducing occupational exposure risk by improved packaging of drugs. J Oncol Pharm Pract. 2004; 10:59. Abstract.
42 Kiffmeyer TK, Niem?ller M, Schirpenbach R et al. Au?enkontaminationen von medikamentenverpackungen: vorschl?ge zum reinigungsverfahen. Krankenhauspharmazie. 2001; 5:207?
43 Lichtenwalner CP. Evaluation of wipe sampling procedures and elemental surface contamination. Am Ind Hyg Assoc J. 1992; 53:657?9.
44 Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Ann Occup Hyg. 2004; 48:237?44.